A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.

被引：3
|
作者：
Takahara, Naminatsu
Isayama, Hiroyuki
Nakai, Yousuke
Ioka, Tatsuya
Kanai, Masashi
Sasaki, Takashi
Furuse, Junji
Koike, Kazuhiko
机构：
[1] Univ Tokyo, Tokyo, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan
[3] Osaka Med Ctr Canc & Cardiovasc Dis, Hepatobiliary & Pancreat Oncol, Osaka, Japan
[4] Kyoto Univ Hosp, Kyoto, Japan
[5] JFCR, Canc Inst Hosp, Tokyo, Japan
[6] Kyorin Univ, Sch Med, Dept Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.TPS514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study
    Ruarus, Alette H.
    Vroomen, Laurie G. P. H.
    Geboers, Bart
    van Veldhuisen, Eran
    Puijk, Robbert S.
    Nieuwenhuizen, Sanne
    Besselink, Marc G.
    Zonderhuis, Barbara M.
    Kazemier, Geert
    de Gruijl, Tanja D.
    van Lienden, Krijn P.
    de Vries, Jan J.
    Scheffer, Hester J.
    Meijerink, Martijn R.
    RADIOLOGY, 2020, 294 (01) : 212 - 220
  • [22] Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
    Takashi Sasaki
    Hiroyuki Isayama
    Yousuke Nakai
    Yukiko Ito
    Hirofumi Kogure
    Osamu Togawa
    Nobuo Toda
    Ichiro Yasuda
    Osamu Hasebe
    Iruru Maetani
    Naoki Sasahira
    Kenji Hirano
    Takeshi Tsujino
    Minoru Tada
    Masao Omata
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 1101 - 1107
  • [23] Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Ito, Yukiko
    Kogure, Hirofumi
    Togawa, Osamu
    Toda, Nobuo
    Yasuda, Ichiro
    Hasebe, Osamu
    Maetani, Iruru
    Sasahira, Naoki
    Hirano, Kenji
    Tsujino, Takeshi
    Tada, Minoru
    Omata, Masao
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (06) : 1101 - 1107
  • [24] A multicenter retrospective study of survival benefits of statins in unresectable or recurrent advanced biliary tract cancer patients
    Tsugaru, K.
    Maruki, Y.
    Okamoto, T.
    Sasahira, N.
    Oshima, K.
    Ishigaki, K.
    Noguchi, M.
    Kizawa, R.
    Sawada, R.
    Saito, Y.
    Hirata, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S128 - S128
  • [25] Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study
    Wagner, Andrej
    Denzer, Ulrike W.
    Neureiter, Daniel
    Kiesslich, Tobias
    Puespoeck, Andreas
    Rauws, Erik A. J.
    Emmanuel, Klaus
    Degenhardt, Nora
    Frick, Ulrich
    Beuers, Ulrich
    Lohse, Ansgar W.
    Berr, Frieder
    Wolkersdoerfer, Gernot W.
    HEPATOLOGY, 2015, 62 (05) : 1456 - 1465
  • [26] Anlotinib in patients with recurrent platinum resistant/refractory ovarian cancer: a prospective, single arm, phase II study
    Shen, Wenbin
    Jing, Chuyu
    Tian, Wenjuan
    Zhang, Wei
    Ren, Yulan
    Shan, Boer
    Wang, Huaying
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (11) : 1764 - 1770
  • [27] A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumbab for Locally Advanced or Metastatic Biliary Tract Cancer
    Iyer, Renuka V.
    Pokuri, Venkata K.
    Groman, Adrienne
    Ma, Wen W.
    Malhotra, Usha
    Iancu, Dan M.
    Grande, Catherine
    Saab, Tanios B.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (07): : 649 - 655
  • [28] Phase II study of S-1 in patients with advanced biliary tract cancer
    H Ueno
    T Okusaka
    M Ikeda
    Y Takezako
    C Morizane
    British Journal of Cancer, 2004, 91 : 1769 - 1774
  • [29] Phase II study of S-1 in patients with advanced biliary tract cancer
    Ueno, H
    Okusaka, T
    Ikeda, M
    Takezako, Y
    Morizane, C
    BRITISH JOURNAL OF CANCER, 2004, 91 (10) : 1769 - 1774
  • [30] A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer.
    Sahai, Vaibhav
    Griffith, Kent A.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345